Online inquiry

IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4681MR)

This product GTTS-WQ4681MR is a type of mRNA modified with 5-Methoxy-UTP, which ecodes the monoclonal antibody that targets MSTN gene. The antibody can be applied in Duchenne muscular dystrophy (DMD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005259.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2660
UniProt ID O14793
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ4681MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9590MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-61610588
GTTS-WQ8845MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IDEC-C2B8
GTTS-WQ9072MR IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMC-A12
GTTS-WQ8109MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HGS-ETR2
GTTS-WQ12630MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ11566MR IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MG-A271
GTTS-WQ6199MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CP-870893
GTTS-WQ6800MR IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DS-8201
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW